We studied patients with valvular heart disease to investigate whether chronic preoperative treatment with angiotensinconverting enzyme (ACE) inhibitors modulates the effect of phenylephrine (PE) on anaesthesia-induced hypotension. Sixty-five patients were enrolled in the study and hypotension developed after anaesthesia in 36 (18 in the control group and 18 in the ACE inhibitor group). These patients received PE infusions, which were increased in a stepwise fashion at 10-min intervals. Increased mean arterial pressure due to PE infusion was significant only in the control group. There was no significant difference in pressor response or change in haemodynamic variables with PE infusion between the two groups. Treatment with ACE inhibitors did not increase the incidence of hypotensive episodes or significantly modify pressor response after anaesthesia in patients with valvular heart disease.
Introduction
Angiotensin-converting enzyme (ACE) inhibitors are known to be highly effective in a variety of vascular disorders. 1 A functional ACE system in the vascular endothelium contributes to the regulation of vascular tone, 2 and bradykinin has been suggested as the mediator responsible for the beneficial effects of ACE inhibitors on endothelial function and on the development of atherosclerosis. 3, 4 Angiotensin II may also contribute to lung vascular remodelling in pulmonary hypertensive disease, and ACE inhibitors have been found to prevent the development of pulmonary hypertension in animal models. 5 Angiotensin-converting enzyme inhibitors alter the physiological mechanisms of arterial blood pressure regulation during anaesthesia, however; patients treated chronically with ACE inhibitors are at higher risk of haemodynamic instability and severe hypotension during the induction of anaesthesia. 6, 7 Moreover, among patients with a history of hypertension, those in the ACE inhibitor treated group were less responsive to the pressor effect of phenylephrine (PE) on hypotension than those in the control group. 8 The haemodynamic consequences of PE during hypothermic cardiopulmonary bypass (CPB) and after separation from CPB have been studied in patients with preserved left ventricular function treated with ACE inhibitors. 9 No reports have been published on the effects of PE on hypotensive events after the induction of general anaesthesia in patients with valvular heart disease chronically treated with ACE inhibitors, however. We aimed, therefore, to study patients with valvular heart disease, to investigate whether chronic pre-operative ACE inhibitor therapy modulates the effect of PE on anaesthesia-induced hypotension.
Patients and methods

PATIENTS
Patients undergoing valvular replacement or repair surgery between January and June 2002 were enrolled in this study. Patients were divided into two groups according to their medical history: those who had not received ACE inhibitors (control group); and those treated with ACE inhibitors for at least 1 month (ACE inhibitors group). Exclusion criteria were: age < 18 years; emergency surgery; chronic treatment with angiotensin II receptor antagonists or calcium channel antagonists; a history of hypertension and insulin-dependent diabetes mellitus; recent myocardial infarction (< 30 days); tricuspid regurgitation of greater than mild degree; and renal insufficiency.
The study was approved by the local Institutional Review Board and all patients gave informed consent.
STANDARD PROCEDURES
All patients received 0.1 mg/kg morphine intramuscularly as a pre-operative medication, 1 h before surgery. All conventional cardiovascular medications (including ACE inhibitors) were administered until the morning of surgery.
In the operating theatre, a 20-gauge radial artery catheter was inserted to allow continuous measurement of systemic arterial pressure. A thermodilutional pulmonary artery catheter (Swan-Ganz ® CCOmbo/SvO2 Model 744HF75, Baxter Healthcare Corp., Irvine, CA, USA) for continuous cardiac output (CO) monitoring was inserted into the right internal jugular vein via an 8.5-Fr introducer (AVA HF, Baxter Healthcare Corp., Irvine, CA, USA). This catheter was used to measure pulmonary artery pressure (PAP), pulmonary capillary wedge pressure (PCWP), central venous pressure (CVP) and CO. Leads II and V 5 of a five-lead electrocardiogram were continuously monitored.
Midazolam (2 -3 mg) and sufentanil (1.5 -2 µg/kg) were used to induce anaesthesia in accordance with standard practice by an anaesthesiologist not involved in the study. Rocuronium (0.6 mg/kg) was given to facilitate ventilation and tracheal intubation. Anaesthesia was maintained with a continuous infusion of sufentanil and 0.4 vol% isoflurane with an inspired oxygen concentration of 60% (oxygen-air mixture). Mechanical ventilation was adjusted to maintain an arterial carbon dioxide tension of 30 -35 mmHg.
After the operation, patients were transferred to the cardiac intensive care unit and monitored according to standard postoperative protocols.
VARIABLES MEASURED
Hypotension was defined as a mean systemic arterial pressure (MAP) either > 15% below the lowest reading recorded by the nurse in the surgical ward during the 24 h preceding the operation, or < 60 mmHg. During induction of anaesthesia, hypotension without bradycardia was treated with a PE (40 µg/ml) infusion; 4 mg of ephedrine was administered intravenously if the heart rate (HR) dropped below 70 beats/min. When a patient developed a defined degree of arterial hypotension within 10 min of anaesthetic induction, haemodynamic variables were recorded (D1), and hypotension was treated with an infusion of PE via the side port of the internal jugular vein catheter. The infusion rate of PE was increased in a stepwise fashion (0.1 µg/kg, 0.2 µg/kg and 0.4 µg/kg per min) at 10-min intervals (D2, D3 and D4, respectively). Skin incision was delayed until the study was completed, to minimize the effect of surgical stimuli on haemodynamic variables. The anaesthesiologists managing the patients and recording the haemodynamic variables were blinded to the patients' group allocation.
Haemodynamic measurements, including HR, MAP, PAP, PCWP, CVP and CO, were recorded before PE infusion and at the end of infusion of each concentration of PE. The systemic vascular resistance index (SVRI) and the pulmonary vascular resistance index (PVRI) were calculated using standard formulae. 10 The ratio of mean PAP to MAP (RBP) and the ratio of PVRI to SVRI (RVRI) were calculated.
STATISTICAL ANALYSIS
All measured values are expressed as mean ± SD, unless otherwise stated. Data were analysed using SPSS (version 10.0, SPSS Inc., Chicago, IL, USA). Baseline data for the two groups were compared using χ 2 analysis or Fisher's exact test and the unpaired t-test. Repeated measures of ANOVA were used to analyse the relationship between the groups and changes in variables according to PE infusion. Dunnett's t-test was used to compare values at D1 with those at D2, D3 and D4 within each group. P-values < 0.05 were considered statistically significant.
Results
Sixty-five patients were recruited to the study: those not receiving ACE inhibitors (control group, n = 35), and those treated with ACE inhibitors for at least a month (ACE inhibitor group, n = 30). Data from 36 patients who developed hypotension after the induction of anaesthesia were analysed, 18 in the control group and 18 in the ACE inhibitor group. Pre-operative data from both groups are summarized in Table 1 . The groups differed only with respect to gender.
In the ACE inhibitor group, patients were treated for a median of 2 months (range 1 -9 months) before surgery with captopril (n = 8, median daily dose 150 mg), ramipril (n = 3, median daily dose 5 mg), cilazapril (n = 3, median daily dose 2.5 mg) or perindopril (n = 2, median daily dose 9 mg). Before induction of anaesthesia, PVRI was significantly higher in the ACE inhibitor group than in the control group (P = 0.046), but other haemodynamic parameters were not significantly different ( Table 2) . Table 3 shows the changes in systemic haemodynamic variables according to PE infusion. The increase in MAP according to PE infusion was significant in the control group (P = 0.008), but not in the ACE inhibitor group. MAP at D4 was significantly higher than at D1 in both groups (P = 0.002 and 0.034 in the control and ACE inhibitor groups, respectively). SVRI significantly increased with PE infusion in the ACE inhibitor group (P = 0.024). SVRI at D4 was significantly higher compared with at D1 in the ACE inhibitor group (P = 0.009). The effects of PE on the pulmonary circulation are HJ Kwak, YL Kwak, YJ Oh et al. ACE inhibitors and phenylephrine responsiveness in valvular heart disease also shown in Table 3 . PCWP significantly increased with PE in the ACE inhibitor group (P = 0.04). PAP and PCWP at D4 were significantly greater than at D1 in the ACE inhibitor group (P = 0.048 and 0.028, respectively). CVP at D4 was significantly greater than at D1 in the control and ACE inhibitor groups (P = 0.029 and 0.028, respectively). PVRI significantly increased with PE in the control group (P = 0.041).
There were no significant within or between group differences in RBP or RVRI (Table 4 ).
Discussion
We found that the pressor response to PE in patients taking ACE inhibitors did not seem to be significantly modified clinically. An increase in MAP with PE was statistically significant in the control group, but this difference is unlikely to have clinical relevance. Moreover, the trend and degree of change in haemodynamic variables according to PE infusion were not significantly different between the control and ACE inhibitor groups. The vasoconstrictive effect of PE was similar in the systemic and pulmonary vasculature in both groups.
Several studies reported that ACE inhibitors exaggerate the hypotensive response to anaesthesia and reduce anaesthetic requirements for induction, especially when they are used as antihypertensive agents. 6 -8 We found no significant difference between the two groups in the amount of sufentanil required for induction and the incidence of developing Use of ephedrine (n) 1 3
All values are expressed as mean ± SD or number of patients. a P < 0.05 compared with control group. ACE inhibitors and phenylephrine responsiveness in valvular heart disease hypotension during and after the induction of anaesthesia, however. In contrast to several previous studies reporting a reduced response to adrenergic agonist in patients on ACE inhibitors, 8, 9 pressor and vasoconstrictive responses to PE were not significantly different in our control and ACE inhibitor groups. This may be because the effects of ACE inhibitors depend on the underlying pathophysiological state and degree of renin angiotensin system activation. 11 Licker et al. 8 found that chronic pre-operative treatment with ACE inhibitors did not influence cardiac autonomic regulation but that sensitivity to norepinephrine was attenuated during and after CPB in the ACE inhibitor group. An attenuated response to adrenergic agonists in patients on ACE inhibitors may be the result of tissue and plasma depletion of angiotensin II, regression of vascular smooth muscle hypertrophy and an improvement in the endothelial vasodilatory function. 9 Most patients included in previous studies had pre-operative hypertension and underwent coronary artery bypass graft surgery. In our study, however, patients had chronic valvular heart disease, and patients with a history of pre-operative hypertension or coronary artery disease were excluded. Ryckwaert Haemodynamic data for patients with valvular heart disease who were treated preoperatively with angiotensin-converting enzyme (ACE) inhibitors (ACE inhibitor group) or did not receive therapy with ACE inhibitors (control group) and who developed hypotension after induction of anaesthesia. These data were obtained before the induction of anaesthesia HJ Kwak, YL Kwak, YJ Oh et al. All values are expressed as mean ± SD. D1, baseline; D2, phenylephrine infused at 0.1 µg/kg per min; D3, phenylephrine infused at 0.2 µg/kg per min; D4, phenylephrine infused at 0.4 µg/kg per min. ACE inhibitors and phenylephrine responsiveness in valvular heart disease of surgery experienced no more hypotension after the induction of anaesthesia than those in a control group. Also, Colson et al. 13 reported that blood pressure in normotensive patients treated with captopril remained stable, and was similar to that of untreated patients during anaesthesia, surgery and CPB; captopril was administered for only 2 days before surgery. Licker et al. 9 reported a greater pressor response to norepinephrine in patients undergoing coronary artery bypass graft surgery than in patients undergoing valvular heart surgery. The authors suggested that this could be related to the higher prevalence of arterial hypertension and of diffuse atherosclerotic regions in patients with coronary artery disease. To our knowledge, no reports have been published on pressor response and changed systemic vasculature in patients with valvular heart disease. It is difficult to clarify from our study results whether the pressor response is attenuated in patients with valvular heart disease regardless of the effect of ACE inhibitor, or if the pressor response is preserved in these patients. Previous studies have shown that the effects of ACE inhibitors on the control of blood pressure and response to vasoconstrictors during anaesthesia appear to be largely affected by the patient's pathophysiology, sympathetic tone and volume status. There are two possible mechanisms for the preserved response to PE in the ACE inhibitor group. First, Nemoto et al. 14 reported that pre-load, but not afterload, was significantly reduced after ACE inhibition with lisinopril in an experimental model with mitral regurgitation. If ACE inhibitors exert little effect on arterial tone in patients with valvular heart disease, it might insignificantly contribute to pressor response in these patients. Secondly, the sympathetic nervous system is considered the organism's main defence against arterial hypotension in humans, and intact sympathoadrenal activation contributes to maintaining the peri-operative cardiocirculatory response in the ACE inhibitor group. In our study, however, there was a reduced response to PE even in the control group, and hypotension developed in more than half of patients after the induction of anaesthesia. This effect occurred despite the fact that we did not use any more anaesthetic drugs than were used in previous studies; this might be attributable to the hypovolaemic status of the patients, which may be responsible for chronic diuretic therapy and poor oral intake. It is conceivable that volume depletion and resultant impaired preload augmentation depressed the pressor response to PE even in the control group. We could not confirm this, however, because: there was no standard monitoring for assessing preload as CVP and PCWP are poorly correlated with left ventricular volume in patients with valvular heart disease; and our study was started before transoesophageal echocardiographic probe insertion.
ACE inhibitors and phenylephrine responsiveness in valvular heart disease
One factor to consider is that most studies observed pressor response after a bolus injection of PE, but in our study, PE was infused with escalating dose. MAP increased significantly only in the control group, despite no difference in change in MAP between the two groups. There could, therefore, have been a difference in pressor response had a high PE dose been given as a bolus in these patients. The PE dose we used was based on the results of a preliminary study to determine the appropriate dose of PE for patients with valvular heart disease. The minimal dose of PE resulting in a significant increase in MAP was 0.1 µg/kg per min (D2 in this study); the dose resulting in a 20% increase in MAP was 0.4 µg/kg per ACE inhibitors and phenylephrine responsiveness in valvular heart disease min (D4). The haemodynamic state before anaesthesia induction was similar for patients treated or not treated with ACE inhibitors, with the exception of the higher PVRI in the ACE inhibitor group. Clozel et al. 15 also observed a higher PAP in patients treated with ACE inhibitors. Some previous reports have also suggested that the beneficial effect of ACE inhibitors in pulmonary hypertension is not accounted for by the vasodilatory action of the drug, but by its anti-remodelling effect. 5, 16 There were several limitations to our study. First, there were statistically significant gender differences between the two study groups ( Table 1) . A previous report found that vasodilators might be more effective at reducing pulmonary hypertension in females than in males, 17 but it is not known whether gender differences affect pressor response in patients on ACE inhibitors. Secondly, this study included a variety of valvular disorders in both groups (Table 1) , and differences in patients' pathophysiologies could have affected our results. It is presumed that patients with significant aortic or mitral incompetence may poorly tolerate an increase in afterload. If the regurgitant region affects the result of this study, pressor response should be more blunted in the ACE inhibitor group, because the adverse effect of vasoconstrictor should be more distinct. When we compared response to PE infusion in terms of changes in MAP, CI and SVRI between patients with and without significant regurgitant region, no significant difference was found (data not shown). Thirdly, the small number of patients involved and the large standard deviations in the haemodynamic data affected statistical accuracy. Finally, PE was started at a relatively higher level of MAP in both groups in this study compared with other studies reporting depressed pressor response in patients on ACE inhibitors. It is not clear whether pressor response depends on the degree of hypotension, however.
We conclude that chronic ACE inhibitor treatment did not increase the incidence of hypotensive episodes or significantly modify pressor response after anaesthesia in patients with valvular heart disease.
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